Delving into the Latest Updates on Shanghai Auson Pharmaceuticals Co., Ltd. with Synapse

Overview

Tags

Digestive System Disorders

Infectious Diseases

Neoplasms

Small molecule drug

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	2
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	2
Chemical drugs	2

Top 5 Target	Count

Sodium channels	1
β-adrenoceptors(Beta adrenergic receptors)	1

The goal of this clinical trial is:
1)To evaluate the pharmacokinetic profiles and safety of 0.5% Timolol Maleate Ophthalmic Gel Forming Solution in healthy adult subjects after multiple dosing; 2)To compare the systemic exposure (Cmax,ss and AUCss) of 0.5% Timolol Maleate Gel in subjects with proliferating superficial infantile hemangioma (completed) with that of 0.5% Timolol Maleate Ophthalmic Gel Forming Solution in healthy adult subjects.
The main questions aim to answer are:
* Pharmacokinetic (PK) profiles of healthy adult subjects
* Safety Evaluation
* To compare the systemic exposure (Cmax,ss and AUCss) of 0.5% timolol maleate gel in subjects with proliferating superficial infantile hemangioma (completed) with that of 0.5% timolol maleate ophthalmic gel forming solution in healthy adult subjects.

Start Date15 Jun 2024

Sponsor / Collaborator

Shanghai Auson Pharmaceuticals Co., Ltd.

CTR20230267

/ CompletedNot Applicable

中国健康受试者空腹和餐后单次口服阿哌沙班分散片和阿哌沙班片的随机、开放、两序列、两周期、双交叉设计的生物等效性研究

[Translation] A randomized, open-label, two-sequence, two-period, double-crossover bioequivalence study of a single oral dose of apixaban dispersible tablets and apixaban tablets in Chinese healthy volunteers after fasting or feeding

主要目的：以上海奥全生物医药科技有限公司提供的阿哌沙班分散片为受试制剂（2.5 mg/片），以Bristol-Myers Squibb Manufacturing Company生产的阿哌沙班片（Eliquis®，2.5mg/片）为参比制剂，比较阿哌沙班分散片和阿哌沙班片在中国健康受试者体内的药代动力学（Pharmacokinetics，PK）行为，评价空腹和餐后口服两种制剂的生物等效性。次要目的： 1、评价中国健康受试者空腹及餐后单次口服阿哌沙班分散片和阿哌沙班片的安全性。 2、收集受试者服用阿哌沙班分散片后15 min内的感官评估问卷（包含口感、口味以及服药后的余味）。

[Translation]

Main purpose: The apixaban dispersible tablets provided by Shanghai Aoquan Biopharmaceutical Technology Co., Ltd. were used as the test preparation (2.5 mg/tablet), and the apixaban tablets (Eliquis®, 2.5 mg/tablet) produced by Bristol-Myers Squibb Manufacturing Company were used as the reference preparation to compare the pharmacokinetic (PK) behavior of apixaban dispersible tablets and apixaban tablets in healthy Chinese subjects, and to evaluate the bioequivalence of the two preparations after fasting and postprandial oral administration. Secondary purpose: 1. To evaluate the safety of single oral administration of apixaban dispersible tablets and apixaban tablets in healthy Chinese subjects after fasting and postprandial administration. 2. To collect sensory evaluation questionnaires (including taste, flavor, and aftertaste after taking the medicine) within 15 minutes after taking the apixaban dispersible tablets.

Start Date14 Feb 2023

Sponsor / Collaborator

Guangzhou Bosto Controlled-Release Pharmaceutical Co Ltd.

[+1]

NCT06677853

/ CompletedPhase 2/3

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II/III Clinical Study to Evaluate the Efficacy and Safety of Timolol Maleate Gel in the Treatment of Proliferating Superficial Infantile Hemangioma

The goal of this clinical trial is to evaluate the safety and efficacy of timolol maleate (TM) gel in subjects with superficial infantile hemangioma (IH) in the proliferative phase. The main question it aims to answer is:
• The primary endpoint (success or failure) assessment was a centralized and independent qualitative assessment based on blinded comparison on B-ultrasonography results and photographs of IH at W24 from baseline.
Researchers will compare TM gel to a placebo (a look-alike substance that contains no drug) to see if TM gel works to treat IH.
Participants will:
* Take the study drug 3 times daily (once in the morning, noon, and evening, respectively) for 24 weeks.
* The family members of patients are instructed to bring the patients to the clinic for regular follow-up visits at Week 4 (W4), Week 12 (W12), and Week 24 (W24) of the treatment period.
* Keep a diary of concomitant medications and adverse events.

Start Date28 Oct 2020

Sponsor / Collaborator

Shanghai Auson Pharmaceuticals Co., Ltd.

100 Clinical Results associated with Shanghai Auson Pharmaceuticals Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai Auson Pharmaceuticals Co., Ltd.

Login to view more data

100 Deals associated with Shanghai Auson Pharmaceuticals Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Auson Pharmaceuticals Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 29 Mar 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

1

Phase 1

NDA/BLA

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

ASN008(Shanghai Auson Pharmaceuticals) ( Sodium channels )	Hepatitis B More	Phase 1
ASN-007(Auson)	Hepatitis B, Chronic More	Preclinical
Timolol Maleate ( β-adrenoceptors )	Capillary Hemangioma More	Pending